The role of probiotics as gastrointestinal infections treatment and prophylaxis: A review
Article Sidebar
Main Article Content
Abstract
Objective: Probiotics are products that contain microorganisms capable of supporting symbiotic relations with native microbiota of many environments. They are widely used and studied due to their capacity to improve biological systems’ overall health. Many hypothesis exist surrounding the mechanisms by which every microbe labelled as probiotic is the cause by which system health is enhanced by its presence. The aim of this review was to compile article’s data concerning the role of different combinations of probiotics used to treat and prevent gastrointestinal conditions, such as antibiotic-associated diarrhea, pseudomembranous colitis, Helicobacter pylori infections, oral, pharyngeal and Salmonella infections. In general, other than presenting excellent safety records, several probiotic combinations registered in clinical trials could prove themselves capable of significantly preventing those infections and some proved to be capable to also treat them once established. The main challenge among the infections studies seems to be oral cavity infections, probably due to microbiota complexity. Nevertheless, probiotics seem to have good prospect for playing a major preventive and protective role in gastrointestinal infections with further investigation to gather sufficient evidence to base treatment protocols.
Downloads
Article Details
Accepted 2021-09-09
Published 2021-09-09
References
Lilly DM, Stillwell RH. Probiotics: growth-promoting factors produced by microorganisms. Science. 1965 Feb 12;147(3659):747-8.
Hill C., Guarner F., Reid G., Gibson G. R., Merenstein D. J., Pot B., et al. . (2014). Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11, 506–514. 10.1038/nrgastro.2014.66
Wilkins T, Sequoia J. Probiotics for Gastrointestinal Conditions: A Summary of the Evidence. Am Fam Physician. 2017 Aug 1;96(3):170-178. PMID: 28762696.
Doron S, Gorbach SL. Probiotics: their role in the treatment and prevention of disease. Expert Rev Anti Infect Ther. 2006 Apr;4(2):261-75. doi: 10.1586/14787210.4.2.261. PMID: 16597207.
Pattani R, Palda VA, Hwang SW, Shah PS. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Med. 2013 May 28;7(2):e56-67. PMID: 24348885; PMCID: PMC3863752
Stadlbauer V. Immunosuppression and probiotics: are they effective and safe? Benef Microbes. 2015;6(6):823-8. doi: 10.3920/BM2015.0065. Epub 2015 Aug 19. PMID: 26287986..
Sanders ME, Akkermans LM, Haller D, Hammerman C, Heimbach J, Hörmannsperger G, Huys G, Levy DD, Lutgendorff F, Mack D, Phothirath P, Solano-Aguilar G, Vaughan E. Safety assessment of probiotics for human use. Gut Microbes. 2010 May-Jun;1(3):164-85. doi: 10.4161/gmic.1.3.12127. Epub 2010 Mar 4. PMID: 21327023; PMCID: PMC3023597.
Happel AU, Barnabas SL, Froissart R, Passmore JS. Weighing in on the risks and benefits of probiotic use in HIV-infected and immunocompromised populations. Benef Microbes. 2018 Feb 27;9(2):239-246. doi: 10.3920/BM2017.0106. Epub 2018 Jan 18. PMID: 29345159.
Jin L, Deng L, Wu W, Wang Z, Shao W, Liu J. Systematic review and meta-analysis of the effect of probiotic supplementation on functional constipation in children. Medicine (Baltimore). 2018 Sep;97(39):e12174. doi: 10.1097/MD.0000000000012174. PMID: 30278490; PMCID: PMC6181519.
Barbut F, Meynard JL. Managing antibiotic associated diarrhoea. BMJ. 2002;324(7350):1345-134612052785
Mekonnen SA, Merenstein D, Fraser CM, Marco ML. Molecular mechanisms of probiotic prevention of antibiotic-associated diarrhea. Curr Opin Biotechnol. 2020 Feb;61:226-234. doi: 10.1016/j.copbio.2020.01.005. Epub 2020 Feb 19. PMID: 32087535; PMCID: PMC7096272.
McFarland LV, Ozen M, Dinleyici EC, Goh S: Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. World J Gastroenterol 2016, 22: 3078–3104.
Gould K, Short G. Probiotics and antibiotic-associated diarrhoea--a logical flaw? J Antimicrob Chemother. 2008 Mar;61(3):761. doi: 10.1093/jac/dkm534. Epub 2008 Jan 28. PMID: 18227093.
Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019 Apr 30;4(4):CD004827. doi: 10.1002/14651858.CD004827.pub5. PMID: 31039287; PMCID: PMC6490796.
Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B, Shekelle PG. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012 May 9;307(18):1959-69. doi: 10.1001/jama.2012.3507. PMID: 22570464.
Song HJ, Shim KN, Jung SA, Choi HJ, Lee MA, Ryu KH, Kim SE, Yoo K. Antibiotic-associated diarrhea: candidate organisms other than Clostridium difficile. Korean J Intern Med. 2008 Mar;23(1):9-15. doi: 10.3904/kjim.2008.23.1.9. PMID: 18363274; PMCID: PMC2686956
Cai J, Zhao C, Du Y, Zhang Y, Zhao M, Zhao Q. Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis. United European Gastroenterol J. 2018 Mar;6(2):169-180. doi: 10.1177/2050640617736987. Epub 2017 Oct 4. PMID: 29511547; PMCID: PMC5833232
Szajewska H, Canani RB, Guarino A, Hojsak I, Indrio F, Kolacek S, Orel R, Shamir R, Vandenplas Y, van Goudoever JB, Weizman Z; ESPGHAN Working Group for ProbioticsPrebiotics. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr. 2016 Mar;62(3):495-506. doi: 10.1097/MPG.0000000000001081. PMID: 26756877.
Fox MJ, Ahuja KD, Robertson IK, Ball MJ, Eri RD. Can probiotic yogurt prevent diarrhoea in children on antibiotics? A double-blind, randomised, placebo-controlled study. BMJ Open. 2015 Jan 14;5(1):e006474. doi: 10.1136/bmjopen-2014-006474. PMID: 25588782; PMCID: PMC4298112.
Mullish BH, Williams HR. Clostridium difficile infection and antibiotic-associated diarrhoea. Clin Med (Lond). 2018 Jun;18(3):237-241. doi: 10.7861/clinmedicine.18-3-237. PMID: 29858434; PMCID: PMC6334067.
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H; IBD guidelines eDelphi consensus group, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27. Erratum in: Gut. 2021 Apr;70(4):1. PMID: 31562236; PMCID: PMC6872448.
Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, Johnston BC. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017 Dec 19;12(12):CD006095. doi: 10.1002/14651858.CD006095.pub4. PMID: 29257353; PMCID: PMC6486212.
Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez-Llorente C, Gil A. Probiotic mechanisms of action. Ann Nutr Metab. 2012;61(2):160-74. doi: 10.1159/000342079. Epub 2012 Oct 2. PMID: 23037511.
McFarland LV. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open. 2014 Aug 25;4(8):e005047. doi: 10.1136/bmjopen-2014-005047. PMID: 25157183; PMCID: PMC4156804.
McFarland LV, Ship N, Auclair J, Millette M. Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence. J Hosp Infect. 2018 Aug;99(4):443-452. doi: 10.1016/j.jhin.2018.04.017. Epub 2018 Apr 24. PMID: 29702133.
Barker AK, Duster M, Valentine S, Hess T, Archbald-Pannone L, Guerrant R, Safdar N. A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO). J Antimicrob Chemother. 2017 Nov 1;72(11):3177-3180. doi: 10.1093/jac/dkx254. PMID: 28961980; PMCID: PMC5890711.
De Wolfe TJ, Eggers S, Barker AK, Kates AE, Dill-McFarland KA, Suen G, Safdar N. Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection. PLoS One. 2018 Sep 28;13(9):e0204253. doi: 10.1371/journal.pone.0204253. PMID: 30265691; PMCID: PMC6161886.
Mills JP, Rao K, Young VB. Probiotics for prevention of Clostridium difficile infection. Curr Opin Gastroenterol. 2018 Jan;34(1):3-10. doi: 10.1097/MOG.0000000000000410. PMID: 29189354; PMCID: PMC6335148.
Evans CT, Johnson S. Prevention of Clostridium difficile Infection With Probiotics. Clin Infect Dis. 2015 May 15;60 Suppl 2:S122-8. doi: 10.1093/cid/civ138. PMID: 25922397.
Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M. Helicobacter pylori and extragastric diseases: A review. World J Gastroenterol. 2018 Aug 7;24(29):3204-3221. doi: 10.3748/wjg.v24.i29.3204. PMID: 30090002; PMCID: PMC6079286.
Suzuki S, Esaki M, Kusano C, Ikehara H, Gotoda T. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World J Gastroenterol. 2019 Apr 28;25(16):1907-1912. doi: 10.3748/wjg.v25.i16.1907. PMID: 31086459; PMCID: PMC6487377.
Wang F, Feng J, Chen P, Liu X, Ma M, Zhou R, Chang Y, Liu J, Li J, Zhao Q. Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis. Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):466-475. doi: 10.1016/j.clinre.2017.04.004. Epub 2017 May 25. PMID: 28552432.
Zheng P.X., Fang H.Y., Yang H.B., Tien N.Y., Wang M.C., Wu J.J. Lactobacillus pentosus strain LPS16 produces lactic acid, inhibiting multidrug-resistant Helicobacter pylori. J. Microbiol. Immunol. Infect. 2016;49:168–174. doi: 10.1016/j.jmii.2014.04.014.
Boyanova L., Gergova G., Markovska R., Yordanov D., Mitov I. Bacteriocin-like inhibitory activities of seven Lactobacillus delbrueckii subsp. bulgaricus strains against antibiotic susceptible and resistant Helicobacter pylori strains. Lett. Appl. Microbiol. 2017;65:469–474. doi: 10.1111/lam.12807.
Aiba Y., Nakano Y., Koga Y., Takahashi K., Komatsu Y. A highly acid-resistant novel strain of Lactobacillus johnsonii No. 1088 has antibacterial activity, including that against Helicobacter pylori, and inhibits gastrin-mediated acid production in mice. Microbiologyopen. 2015;4:465–474. doi: 10.1002/mbo3.252.
Aiba Y., Ishikawa H., Tokunaga M., Komatsu Y. Anti-Helicobacter pylori activity of non-living, heat-killed form of lactobacilli including Lactobacillus johnsonii No.1088. FEMS Microbiol. Lett. 2017;364 doi: 10.1093/femsle/fnx102.
Ji J, Yang H. Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy. Int J Mol Sci. 2020 Feb 8;21(3):1136. doi: 10.3390/ijms21031136. PMID: 32046317; PMCID: PMC7037652.
Chakravarty K, Gaur S. Role of Probiotics in Prophylaxis of Helicobacter pylori Infection. Curr Pharm Biotechnol. 2019;20(2):137-145. doi: 10.2174/1389201020666190227203107. PMID: 30827235.
Becker DE. Drug allergies and implications for dental practice. AnesthProg. 2013;60:188–97.
Becker DE. Antimicrobial drugs. AnesthProg. 2013;60:111–22
Zarco MF, Vess TJ, Ginsburg GS. The oral microbiome in health and disease and the potential impact on personalized dental medicine. Oral Diseases. 2012;18:109–20.
Zijnge V, van Leeuwen MB, Degener JE, Abbas F, Thurnheer T, Gmür R. Oral biofilm architecture on natural teeth. PLoS One. 2010;5:e9321
Piwat S, Sophatha B, Teanpaisan R. An assessment of adhesion, aggregation and surface charges of Lactobacillus strains derived from the human oral cavity. LettApplMicrobiol. 2015;61:98–105.
Laleman I, Yilmaz E, Ozcelik O, Haytac C, Pauwels M, Herrero ER. The effect of a streptococci containing probiotic in periodontal therapy: a randomized controlled trial. J Clin Periodontol. 2015;42:1032–41.
Morales A, Carvajal P, Silva N, Hernandez M, Godoy C, Rodriguez G. Clinical Effects of Lactobacillus rhamnosus in Non-Surgical Treatment of Chronic Periodontitis: A Randomized Placebo-Controlled Trial With 1-Year Follow-Up. J Periodontol. 2016 Aug;87(8):944–52.
Faran Ali SM, Tanwir F. Oral microbial habitat a dynamic entity. J Oral Biol Craniofac Res. 2012;2:181–7.
Laleman I, Detailleur V, Slot DE, Slomka V, Quirynen M, Teughels W. Probiotics reduce mutans streptococci counts in humans: a systematic review and meta-analysis. Clin Oral Investig. 2014;18:1539–52.
Taipale T, Pienihäkkinen K, Salminen S, Jokela J, Söderling E. Bifidobacteriumanimalis subsp. lactis BB-12 administration in early childhood: a randomized clinical trial of effects on oral colonization by mutans streptococci and the probiotic. Caries Res. 2012;46:69–77.
Twetman S, Keller MK. Probiotics for caries prevention and control. Adv Dent Res. 2012;24:98–102.
Gruner D, Paris S, Schwendicke F. Probiotics for managing caries and periodontitis: Systematic Review and Meta-Analysis. J Dent. 2016;48:16–25.
Iheozor-Ejiofor Z, Worthington HV, Walsh T, O'Malley L, Clarkson JE, Macey R. Water fluoridation for the prevention of dental caries. Cochrane Database Syst Rev. 2015;6:CD010856.
Seminario-Amez M, López-López J, Estrugo-Devesa A, Ayuso-Montero R, Jané-Salas E. Probiotics and oral health: A systematic review. Med Oral Patol Oral Cir Bucal. 2017 May 1;22(3):e282-e288. doi: 10.4317/medoral.21494. PMID: 28390121; PMCID: PMC5432076.
Shimauchi H, Mayanagi G, Nakaya S, Minamibuchi M, Ito Y, Yamaki K. Improvement of periodontal condition by probiotics with Lactobacillus salivariusWB21: a randomized, double-blind, placebo-controlled study. J Clin Periodontol. 2008;35:897–905
Morales A, Carvajal P, Silva N, Hernandez M, Godoy C, Rodriguez G. Clinical Effects of Lactobacillus rhamnosus in Non-Surgical Treatment of Chronic Periodontitis: A Randomized Placebo-Controlled Trial With 1-Year Follow-Up. J Periodontol. 2016 Aug;87(8):944–52.
Alves-Barroco C, Paquete-Ferreira J, Santos-Silva T, Fernandes AR. Singularities of Pyogenic Streptococcal Biofilms - From Formation to Health Implication. Front Microbiol. 2020 Dec 23;11:584947. doi: 10.3389/fmicb.2020.584947. PMID: 33424785; PMCID: PMC7785724.
Taverniti V, Minuzzo M, Arioli S, Junttila I, Hämäläinen S, Turpeinen H, Mora D, Karp M, Pesu M, Guglielmetti S. In vitro functional and immunomodulatory properties of the Lactobacillus helveticus MIMLh5-Streptococcus salivarius ST3 association that are relevant to the development of a pharyngeal probiotic product. Appl Environ Microbiol. 2012 Jun;78(12):4209-16. doi: 10.1128/AEM.00325-12. Epub 2012 Apr 13. PMID: 22504812; PMCID: PMC3370528.
Wescombe PA, et al. 2011. Salivaricin 9, a new lantibiotic produced by Streptococcus salivarius. Microbiology 157:1290–1299
Guglielmetti S, et al. 2010. Oral bacteria as potential probiotics for the pharyngeal mucosa. Appl. Environ. Microbiol. 76:3948–3958
Bidossi A, De Grandi R, Toscano M, Bottagisio M, De Vecchi E, Gelardi M, Drago L. Probiotics Streptococcus salivarius 24SMB and Streptococcus oralis 89a interfere with biofilm formation of pathogens of the upper respiratory tract. BMC Infect Dis. 2018 Dec 13;18(1):653. doi: 10.1186/s12879-018-3576-9. PMID: 30545317; PMCID: PMC6292094.
Humphreys GJ, McBain AJ. Antagonistic effects of Streptococcus and Lactobacillus probiotics in pharyngeal biofilms. Lett Appl Microbiol. 2019 Apr;68(4):303-312. doi: 10.1111/lam.13133. Epub 2019 Mar 13. PMID: 30776138.
Popa GL, Papa MI. Salmonella spp. infection - a continuous threat worldwide. Germs. 2021 Mar 15;11(1):88-96. doi: 10.18683/germs.2021.1244. PMID: 33898345; PMCID: PMC8057844.
Nissle A. Explanations of the significance of colonic dysbacteria & the mechanism of action of E. coli therapy (mutaflor) Medizinische. 1959;4:1017–1022.
Deriu E, Liu JZ, Pezeshki M, Edwards RA, Ochoa RJ, Contreras H, Libby SJ, Fang FC, Raffatellu M. Probiotic bacteria reduce salmonella typhimurium intestinal colonization by competing for iron. Cell Host Microbe. 2013 Jul 17;14(1):26-37. doi: 10.1016/j.chom.2013.06.007. PMID: 23870311; PMCID: PMC3752295.
Crouch ML, Castor M, Karlinsey JE, Kalhorn T, Fang FC. Biosynthesis and IroC-dependent export of the siderophore salmochelin are essential for virulence of Salmonella enterica serovar Typhimurium. Molecular microbiology. 2008;67:971–983.
Smith IM, Baker A, Arneborg N, Jespersen L. Non-Saccharomyces yeasts protect against epithelial cell barrier disruption induced by Salmonella enterica subsp. enterica serovar Typhimurium. Lett Appl Microbiol. 2015 Nov;61(5):491-7. doi: 10.1111/lam.12481. Epub 2015 Sep 22. PMID: 26280244.
Neveling DP, van Emmenes L, Ahire JJ, Pieterse E, Smith C, Dicks LMT. Effect of a Multi-Species Probiotic on the Colonisation of Salmonella in Broilers. Probiotics Antimicrob Proteins. 2020 Sep;12(3):896-905. doi: 10.1007/s12602-019-09593-y. PMID: 31784950.
Carter A, Adams M, La Ragione RM, Woodward MJ. Colonisation of poultry by Salmonella Enteritidis S1400 is reduced by combined administration of Lactobacillus salivarius 59 and Enterococcus faecium PXN-33. Vet Microbiol. 2017 Feb;199:100-107. doi: 10.1016/j.vetmic.2016.12.029. Epub 2016 Dec 26. PMID: 28110775.
Levkut M, Pistl J, Lauková' A, Revajová V, Herich R, Sevcíková Z, Strompfová V, Szabóová R, Kokincáková T. Antimicrobial activity of Enterococcus faecium ef 55 against Salmonella enteritidis in chicks. Acta Vet Hung. 2009 Mar;57(1):13-24. doi: 10.1556/AVet.57.2009.1.2. PMID: 19457770.
de Oliveira JE, van der Hoeven-Hangoor E, van de Linde IB, Montijn RC, van der Vossen JM. In ovo inoculation of chicken embryos with probiotic bacteria and its effect on posthatch Salmonella susceptibility. Poult Sci. 2014 Apr;93(4):818-29. doi: 10.3382/ps.2013-03409. PMID: 24706958.
Mazkour S, Shekarforoush SS, Basiri S, Nazifi S, Yektaseresht A, Honarmand M. Effects of two probiotic spores of Bacillus species on hematological, biochemical, and inflammatory parameters in Salmonella Typhimurium infected rats. Sci Rep. 2020 May 15;10(1):8035. doi: 10.1038/s41598-020-64559-3. PMID: 32415253; PMCID: PMC7229222.
Velazquez EM, Nguyen H, Heasley KT, Saechao CH, Gil LM, Rogers AWL, Miller BM, Rolston MR, Lopez CA, Litvak Y, Liou MJ, Faber F, Bronner DN, Tiffany CR, Byndloss MX, Byndloss AJ, Bäumler AJ. Endogenous Enterobacteriaceae underlie variation in susceptibility to Salmonella infection. Nat Microbiol. 2019 Jun;4(6):1057-1064. doi: 10.1038/s41564-019-0407-8. Epub 2019 Mar 25. PMID: 30911125; PMCID: PMC6533147.
Gut AM, Vasiljevic T, Yeager T, Donkor ON. Salmonella infection - prevention and treatment by antibiotics and probiotic yeasts: a review. Microbiology (Reading). 2018 Nov;164(11):1327-1344. doi: 10.1099/mic.0.000709. Epub 2018 Aug 23. PMID: 30136920.
Lönnermark E, Lappas G, Friman V, Wold AE, Backhaus E, Adlerberth I. Effects of probiotic intake and gender on nontyphoid Salmonella infection. J Clin Gastroenterol. 2015 Feb;49(2):116-23. doi: 10.1097/MCG.0000000000000120. PMID: 24667592.
Palmer JD, Piattelli E, McCormick BA, Silby MW, Brigham CJ, Bucci V. Engineered Probiotic for the Inhibition of Salmonella via Tetrathionate-Induced Production of Microcin H47. ACS Infect Dis. 2018 Jan 12;4(1):39-45. doi: 10.1021/acsinfecdis.7b00114. Epub 2017 Sep 20. PMID: 28918634; PMCID: PMC5766358.